Abrégé

in vivoin vivo, and more particularly in cancer cells, and tissues thereof.

Classes IPC  ?

• C07F 17/02 - Metallocènes de métaux des groupes 8, 9 ou 10 du tableau périodique
• A61P 35/00 - Agents anticancéreux
• A61K 9/107 - Émulsions
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique

Abrégé

blockstatblockblockstatblockblockstatblockblockstatblockblock-styrene) in the form of the membrane to a reaction with 1-methylpyrrolidine to form a quaternary 1,1-dimethylpyrrolidinium salt covalently bound to the benzene rings of the styrene units. Furthermore, an anion-exchange membrane obtainable by this method is provided.

Classes IPC  ?

• C08J 5/22 - Bandes, membranes ou diaphragmes
• B01D 71/82 - Matériaux macromoléculaires non prévus spécifiquement dans un seul des groupes caractérisés par la présence de groupes déterminés, p. ex. introduits par un post-traitement chimique
• B01J 47/012 - Procédés d'échange d'ions en généralAppareillage à cet effet utilisant un appareil portable d’échange d’ions
• C08F 8/24 - Haloalkylation

Abrégé

NN-(2- hydroxypropyl)methacrylamide), poly(2-oxazoline); to which at least one hydrophobically-active anchor is attached via a covalent bond, said hydrophobically-active anchor enabling suppression of non-specific interactions in immuno assays. The invention further relates to a method of preparing and to the use of said macromolecular blockers for capturing of specific antibodies or antigens or other molecules on the surface of the solid phase. The present invention enables to replace animal-derived proteins with a synthetic macromolecular blocker that is not only more effective in blocking activity itself, but it is also defined in its structure, has high batch-to-batch reproducibility, and does not need to be tested for the presence of viruses and other pathogens.

Classes IPC  ?

• A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
• C08F 2/38 - Polymérisation utilisant des régulateurs, p. ex. des agents d'arrêt de chaîne
• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08G 73/02 - Polyamines

Produits et services

Chemical substances, chemical materials and chemical preparations, and natural elements (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); chemical substances for analysis in laboratories; chemical compositions and materials for use in science; chemicals for use in separation techniques [other than medical or veterinary]; catalysts for chemical and biochemical processes; chemical reagents, other than for medical or veterinary purposes; industrial chemicals; particulate material for use in chromatographic processes [other than medical]; diagnostic chemicals [other than for medical or veterinary use]; diagnostic preparations for scientific or research use; unprocessed synthetic polymers; diagnostic testing materials, other than for medical use; reagents for use in analytical tests [other than for medical or veterinary purposes]; copolymers; chemical polymers; polymers for use in the analysis of biochemicals; chemicals for use in immuno-assay testing [other than medical or veterinary]; diagnostic kits comprising specimen receptors and reagents for testing for selected bacteria. Chemical test reagents [medical]; chemical reagents for medical use; diagnostic substances for medical use; diagnostic chemical reagents for medical use; chemical preparations for medical purposes; chemical substances for use in separation for medical and veterinary purposes; chemicals for use in chromatography [medical and veterinary]; diagnostic testing materials for medical use; in vitro diagnostic preparations for medical use; reagents for in-vitro laboratory use [for medical purposes]; immunoassay reagents for medical use; diagnostic preparations for medical purposes. Medical apparatus and instruments; medical apparatus for use in cellular analysis and diagnosis; diagnostic apparatus for medical purposes; testing apparatus for medical purposes; robotics for medical purposes (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); medical apparatus for measuring and displaying data measured from bodily fluids, including accessories; blood testing apparatus; medical apparatus for measuring biochemical changes in the blood; membranes for filtration [medical]; tools for medical diagnostics. Chemical analysis; life science research and development services; scientific research for medical purposes; pharmaceutical research; biological analysis; analytical laboratory services; analysis in the field of molecular biology; biochemistry research services; chemistry services; chemical research and analysis services; biological research; biological laboratory services; laboratory testing; design and development of medical diagnostic apparatus; consultancy in the fields of laboratory, measuring and medical equipment (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); consultancy in the fields of measuring, testing and analysis; design and development of computer hardware and software for healthcare requirements; computer programming in the medical field; providing information on the subject of scientific research in the field of biochemistry and biotechnology; science and technology services (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); technological consultancy; computer aided diagnostic testing services; laboratory services (terms too vague in the opinion of the International Bureau – Rule 13 (2) (b) of the Regulations); none of the foregoing relating to the field of security or cybersecurity hardware, software or services. Medical diagnostic services; medical laboratory services for the analysis of samples taken from patients; medical analysis services for diagnostic and treatment purposes provided by medical laboratories.

Abrégé

The present invention relates to a fluorescently labelled polymer, to which a fluorescent label is bound in an amount of from 0.1 to 10 mol %, related to the total number of monomer units. The fluorescence of said polymer is activated in tumour tissue, therefore a significant visualization of tumour tissue is provided. It may therefore be used in diagnostic methods or image-guided surgery. Preferably, the fluorescently labelled polymer is targeted towards tumour cells and tumour neovasculature using specific targeting groups. The present invention further relates to methods of preparation of the fluorescently labelled polymer, and its use as a fluorescence probe in diagnostic methods as a contrast agent for tumour visualization, whole body imaging and/or for image-guided surgery.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• C08F 220/56 - AcrylamideMéthacrylamide
• C08F 8/32 - Introduction d'atomes d'azote ou de groupes contenant de l'azote par réaction avec des amines

Produits et services

Chemical analysis; life science research and development services; scientific research for medical purposes; pharmaceutical research; biological analysis; analytical medical laboratory services; analysis in the field of molecular biology; biochemistry research services; laboratory testing and contract assay development chemistry services; chemical research and analysis services; biological research; biological laboratory services; pharmaceutical, medical and dental laboratory services, namely, laboratory testing; design and development of medical diagnostic apparatus; [ medical consultancy in the fields of laboratory research, testing, measuring, and analysis; medical consultancy in the field of design and development of medical equipment; ] consultancy in the fields of medical measuring, testing and analysis; design and development of computer hardware and software for healthcare requirements; computer programming in the medical field; providing information on the subject of scientific research in the field of biochemistry and biotechnology; [ science and technology services, namely scientific research, analysis and testing in the fields of biochemistry and biotechnology; ] technological consultancy in the fields of biochemistry and biotechnology; [ scientific and ] technological services, namely, computer aided testing for others in the fields of biochemistry and biotechnology; [ medical laboratory services; ] none of the foregoing relating to the field of security or cybersecurity hardware, software or services Medical diagnostic services; medical services for the analysis of samples taken from patients for diagnostic and treatment purposes provided by medical laboratories; medical analysis services for diagnostic and treatment purposes provided by medical laboratories [ Chemical substances and chemical preparations for scientific purposes, other than for medical or veterinary use; ] chemical substances for analysis in laboratories, other than for medical or veterinary purposes; chemical compositions for use in science, other than for medical or veterinary use; chemicals for use in separation techniques, other than medical or veterinary, namely, oil separating chemicals; catalysts for chemical and biochemical processes; chemical reagents, other than for medical or veterinary purposes; industrial chemicals; particulate material for use in chromatographic processes other than for medical use, namely, chromatography separation media for separation of a mixture into components; diagnostic chemicals other than for medical or veterinary use; diagnostic preparations for scientific or research use; unprocessed synthetic polymers; diagnostic testing materials in the nature of paramagnetic particles, separation membranes, reagent bearing test strips, cell culture media supplements and reagents, other than for medical use; reagents for use in analytical tests, other than for medical or veterinary purposes; unprocessed polymers for use in the analysis of biochemicals; chemicals for use in immuno-assay testing, other than medical or veterinary use; diagnostic kits comprising specimen receptors and reagents for testing for selected bacteria, other than for medical or veterinary purposes Chemical test reagents for medical purposes; chemical reagents for medical use; diagnostic substances for medical use; diagnostic chemical reagents for medical use; chemical preparations for medical purposes, namely, for blocking of nonspecific interactions in the diagnostic assays; chemical substances for use in separation for medical and veterinary purposes; chemicals for use in chromatography for medical and veterinary purposes, namely, chromatography separation media for separation of a mixture into components; diagnostic testing materials in the nature of paramagnetic particles, separation membranes, medical diagnostic test stripsand reagents for medical use for blood, urine, and body fluids testing; in vitro diagnostic preparations for medical use; reagents for in-vitro laboratory use for medical purposes; immunoassay reagents for medical use; diagnostic preparations for medical purposes Medical apparatus and instruments, namely, multiwell plates, point of care instruments and in vitro diagnostics analyzers; medical apparatus for use in cellular analysis and diagnosis for testing of cellular biomarkers in blood, urine, body fluids, in vitro cultured cells; diagnostic apparatus for medical purposes for testing of biomarkers in blood, urine, and body fluids, cells and tissues; testing apparatus for medical purposes for testing of biomarkers in blood, urine, body fluids, cells and tissues; [ robotics for medical purposes, namely, surgical robots; ] medical apparatus for measuring and displaying data measured from bodily fluids, including accessories in the nature of tubes and systems for body fluids storage; blood testing apparatus; medical apparatus for measuring biochemical changes in the blood; tools for sample preparation for medical diagnostics testing

Produits et services

Chemical substances, chemical materials and chemical preparations, and natural elements; Chemical substances for analysis in laboratories; Chemical compositions and materials for use in science; Chemicals for use in separation techniques [other than medical or veterinary]; Catalysts for chemical and biochemical processes; Chemical reagents, other than for medical or veterinary purposes; Industrial chemicals; Particulate material for use in chromatographic processes [other than medical]; Diagnostic chemicals [other than for medical or veterinary use]; Diagnostic preparations for scientific or research use; Unprocessed synthetic polymers; Diagnostic testing materials, other than for medical use; Reagents for use in analytical tests [other than for medical or veterinary purposes]; Copolymers; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemicals for use in immuno-assay testing [other than medical or veterinary]; Diagnostic kits comprising specimen receptors and reagents for testing for selected bacteria. Chemical test reagents [medical]; Chemical reagents for medical use; Diagnostic substances for medical use; Diagnostic chemical reagents for medical use; Chemical preparations for medical purposes; Chemical substances for use in separation for medical and veterinary purposes; Chemicals for use in chromatography [medical and veterinary]; Diagnostic testing materials for medical use; In vitro diagnostic preparations for medical use; Reagents for in-vitro laboratory use [for medical purposes]; Immunoassay reagents for medical use; Diagnostic preparations for medical purposes. Medical apparatus and instruments; Medical apparatus for use in cellular analysis and diagnosis; Diagnostic apparatus for medical purposes; Testing apparatus for medical purposes; Robotics for medical purposes; Medical apparatus for measuring and displaying data measured from bodily fluids, including accessories; Blood testing apparatus; Medical apparatus for measuring biochemical changes in the blood; Membranes for filtration [medical]; Diagnostic apparatus for medical purposes; Tools for medical diagnostics. Chemical analysis; Life science research and development services; Scientific research for medical purposes; Pharmaceutical research; Biological analysis; Analytical laboratory services; Analysis in the field of molecular biology; Biochemistry research services; Chemistry services; Chemical research and analysis services; Biological research; Biological laboratory services; Laboratory testing; Design and development of medical diagnostic apparatus; Consultancy in the fields of laboratory, measuring and medical equipment; Consultancy in the fields of measuring, testing and analysis; Design and development of computer hardware and software for healthcare requirements; Computer programming in the medical field; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Science and technology services; Technological consultancy; Computer aided diagnostic testing services; Laboratory services; none of the foregoing relating to the field of security or cybersecurity hardware, software or services. Medical diagnostic services; Medical laboratory services for the analysis of samples taken from patients; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories.

Abrégé

The invention provides a block copolymer poly(styrene-block-C2-C4-alkylene-stat-C2-C4-alkylene-block-styrene), wherein the benzene cores of the styrene units are substituted by sulfomethyl groups. Furthermore, the invention provides a cation exchange membrane consisting of or comprising said block copolymer. Yet furthermore, a method of preparation and use of the copolymer and/or the membrane are disclosed.

Classes IPC  ?

• C08F 8/36 - SulfonationSulfatation
• C08F 8/06 - Oxydation
• C08J 5/22 - Bandes, membranes ou diaphragmes
• C08F 297/04 - Composés macromoléculaires obtenus en polymérisant successivement des systèmes différents de monomère utilisant un catalyseur de type ionique ou du type de coordination sans désactivation du polymère intermédiaire utilisant un catalyseur du type anionique en polymérisant des monomères vinylaromatiques et des diènes conjugués
• C08L 53/02 - Compositions contenant des copolymères séquencés possédant au moins une séquence d'un polymère obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carboneCompositions contenant des dérivés de tels polymères contenant des monomères vinylaromatiques et des diènes conjugués
• B01D 61/00 - Procédés de séparation utilisant des membranes semi-perméables, p. ex. dialyse, osmose ou ultrafiltrationAppareils, accessoires ou opérations auxiliaires, spécialement adaptés à cet effet
• B01D 71/80 - Polymères séquencés
• H01M 8/00 - Éléments à combustibleLeur fabrication

Abrégé

The present invention relates to a process for ion irradiation of a particulate substrate containing the steps of embedding particulate substrate in a solid matrix having 10B atoms, and exposing the matrix obtained in the previous step to a neutron flux to give irradiated particulate substrate. The process is extremely effective and amenable to large scale and is particularly suitable for producing irradiated nanodiamonds and irradiated SiC particles.

Classes IPC  ?

• B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage
• C01B 32/28 - Post-traitement, p. ex. purification, irradiation, séparation ou récupération
• C01B 32/956 - Carbure de silicium

Abrégé

The present invention relates to a method of synthesis of a biodegradable polyurethane foam, comprising the following steps: i) mixing of at least one aliphatic isocyanate bearing at least two isocyanate groups with at least one saccharide in weight ratio of from 1:1 to 30:1 to form a saccharide-isocyanate precursor; ii) homogenization of the saccharide-isocyanate precursor from step i) with 20 to 70 % (w/w) of at least one biodegradable aliphatic polyester-ether polyol having molecular mass in the range of from 0 to 10 000 g/mol and hydroxyl number from 10 to 100 mgKOH/g, 1 to 5 % (w/w) of water, and 1 to 10 % (w/w) of at least one blowing agent other than water, related to the total weight of the resulting mixture; iii) foaming of the homogenized mixture from step ii) at the temperature of from 20 to 100 °C, resulting in the biodegradable polyurethane foam comprising incorporated saccharide. The invention further relates to a biodegradable polyurethane foam obtainable by this method, to a biodegradable polyurethane foam-based material for saccharide-cleaving enzyme production and to the use thereof.

Classes IPC  ?

• C08G 18/16 - Catalyseurs
• C08G 18/18 - Catalyseurs contenant des amines secondaires ou tertiaires ou leurs sels
• C08G 18/24 - Catalyseurs contenant des composés métalliques de l'étain
• C08G 18/32 - Composés polyhydroxylésPolyaminesHydroxyamines
• C08G 18/40 - Composés de haut poids moléculaire
• C08G 18/42 - Polycondensats contenant des groupes ester carboxylique ou carbonique dans la chaîne principale
• C08G 18/64 - Composés macromoléculaires non prévus dans les groupes
• C08G 18/66 - Composés des groupes , ou
• C08G 18/73 - Polyisocyanates ou polyisothiocyanates acycliques
• C08G 18/79 - Polyisocyanates ou polyisothiocyanates contenant des hétéro-atomes autres que l'azote, l'oxygène ou le soufre de l'isocyanate ou de l'isothiocyanate de l'azote caractérisés par le polyisocyanate utilisé, celui-ci contenant des groupes formés par oligomérisation d'isocyanates ou d'isothiocyanates
• C08J 9/08 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement utilisant des gaz de gonflage produits par un agent de gonflage introduit au préalable par un agent chimique de gonflage dégageant de l'anhydride carbonique
• C12N 1/20 - BactériesLeurs milieux de culture
• C12R 1/00 - Micro-organismes
• C12N 9/42 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-glucosidiques-1, 4, p. ex. cellulase
• C12N 11/093 - Polyuréthanes
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

The present invention relates to the preparation, structure and properties of water-soluble polymer therapeutics based on cytarabine derivatives, intended primarily for the treatment of leukaemias and non-Hodgkin's lymphomas in human medicine. Cytarabine is attached to the polymer backbone via amide bond to an amino acid or oligopeptidic sequence situated within the polymer side chain. The structure of cytarabine acylamides enables the stability of the whole polymeric system during blood circulation, and thus its sufficient accumulation in the neoplastic tissue, wherein the drug is allowed to be released hydrolytically. The present invention further relates to the polymeric cytostatics, which is stable in blood stream, to the pharmaceutical composition and use thereof in medicine.

Classes IPC  ?

• A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène

Abrégé

N-in situin situ modification of the end groups of the linear statistical copolymer, optionally, binding a biologically active molecule to the ends of the polymer chain. The present invention further relates to a method of preparation of a conjugate of the linear statistical copolymer with a drug by means of a pH-sensitive hydrolysable hydrazone bond.

Classes IPC  ?

• A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61K 49/00 - Préparations pour examen in vivo
• C08F 20/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08F 20/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide
• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08F 220/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide

Abrégé

N2q2rpqrr are independently selected from 1, 2 and 3; Y is selected from the group consisting of a bond, - C(=0)-NH-, -NH-C(=0)-, -NH-C(=S)-NH-; the molecular weight Mn of the linear semitelechelic copolymer is in the range of from 10,000 to 100,000 g/mol; and the fluorophore has a molecular weight in the range of from 350 to 1,500 g/mol, an excitation wavelength in the range of from 300 to 850 nm and an emission wavelength in the range of from 350 to 1,200 nm. The present invention further relates to a fluorescent probe, a conjugation kit, a method of their preparation and to the use thereof.

Classes IPC  ?

• C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
• C08F 220/56 - AcrylamideMéthacrylamide
• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08F 220/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• C08L 33/26 - Homopolymères ou copolymères de l'acrylamide ou de la méthacrylamide

Abrégé

galacto galacto-configuration, which are effective as galectin inhibitors. These glycopolymers can be used as drugs for the therapy and prevention of oncological diseases associated with overproduction of galectins, especially of human galectin-3 (Gal-3).

Classes IPC  ?

• A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
• A61P 35/00 - Agents anticancéreux
• C08F 20/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide

Abrégé

The present invention provides a liquid polymeric wound dressing composition having an anti- inflammatory effect, comprising a polymer network comprising at least one type of structural units derived from sterically hindered amines, at least one type of structural units derived from alkyloxysilanes and at least one type of structural units derived from alkylsiloxanes.

Classes IPC  ?

• C08F 230/08 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et contenant du phosphore, du sélénium, du tellure ou un métal contenant un métal contenant du silicium
• C09D 143/04 - Homopolymères ou copolymères de monomères contenant du silicium
• C09J 143/04 - Homopolymères ou copolymères de monomères contenant du silicium

Abrégé

The present invention relates to a process for ion irradiation of a particulate substrate, comprising the steps of: embedding particulate substrate in a solid matrix comprising 10B atoms; and exposing the matrix obtained in the previous step to a neutron flux; to give irradiated particulate substrate. The process of the invention is extremely effective and amenable to large scale. It is particularly suitable for producing irradiated nanodiamonds and irradiated SiC particles.

Classes IPC  ?

• C01B 32/28 - Post-traitement, p. ex. purification, irradiation, séparation ou récupération
• C01B 32/956 - Carbure de silicium

Abrégé

The invention provides a wound healing preparation with antimicrobial and antiinflammatory activity for accelerating wound healing, which contains at least two biocompatible polymers in the form of interpenetrating networks. One polymer network may be prepared by radical polymerization or poly addition and may contain at least one type of structural units derived from tertiary amines, and another polymer network may be prepared by radical polymerization or polyaddition and may contain at least one type of structural units derived from sterically hindered amines.

Classes IPC  ?

• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/785 - Polymères contenant de l'azote
• A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
• A61K 31/79 - Polymères de vinylpyrrolidone
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif
• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• G01N 33/531 - Production de matériaux de tests immunochimiques
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• A61K 49/00 - Préparations pour examen in vivo
• A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène

Abrégé

The present invention provides an odor deterrent which consists of a hollow closed housing (A) having a cavity filled with a porous carrier (B) containing an odorous component (C), wherein - the housing (A) is made of a biodegradable waterproof polymeric material containing at least 30 wt. % of a component selected from starch ester, polyhydroxybutyrate having the weight average molar mass of at least 20 000 g/mol, polylactide having the weight average molar mass of at least 10 000 g/mol, polycaprolactone having the weight average molar mass of at least 30 000 g/mol, polyurethane obtained by reacting a polyester or polyether-ester polyol and an aliphatic diisocyanate, and mixtures thereof, and up to 70 wt. % of an inert inorganic filler or a cellulosic filler, and optionally a plastifier, - the carrier (B) of the odorous component is made of a porous polymeric material containing at least 70 wt. % of a component selected from starch, starch ester, cellulose, polyurethane obtained by reacting a polyester or polyether-ester polyol and an aliphatic diisocyanate, and mixtures thereof, and up to 30 wt. % of an inert inorganic filler or a cellulosic filler, and optionally a plastifier, and - the odorous component (C) is selected from the group consisting of monocarboxylic acids having 4 to 6 carbons in the chain, a mixture of monocarboxylic acids having 4 to 6 carbon atoms in the chain, esters of said monocarboxylic acids, anhydrides of said monocarboxylic acids.

Classes IPC  ?

• C08G 18/48 - Polyéthers
• A01M 29/12 - Épouvantails ou dispositifs répulsifs, p. ex. pour oiseaux utilisant des substances odorantes, p. ex. des arômes, phéromones ou agents chimiques
• C08G 18/64 - Composés macromoléculaires non prévus dans les groupes
• C08G 18/79 - Polyisocyanates ou polyisothiocyanates contenant des hétéro-atomes autres que l'azote, l'oxygène ou le soufre de l'isocyanate ou de l'isothiocyanate de l'azote caractérisés par le polyisocyanate utilisé, celui-ci contenant des groupes formés par oligomérisation d'isocyanates ou d'isothiocyanates
• C08G 18/24 - Catalyseurs contenant des composés métalliques de l'étain
• C08G 18/40 - Composés de haut poids moléculaire
• C08G 18/42 - Polycondensats contenant des groupes ester carboxylique ou carbonique dans la chaîne principale

Abrégé

The invention provides a polymeric thermoplastic biodegradable composition incorporating an antibiotic, in particular for production of inserts for the treatment and prevention of local infections, consisting of (a) at least one plastified polysaccharide component, which is selected from starch, a mixture of starch and maltodextrin, esterified starch, and a mixture of esterified starch and esterified maltodextrin, wherein maltodextrin is a mixture of oligosaccharides having the dextrose equivalent of at most 25, whereas the polysaccharide component further contains an antibiotic, and (b) a polyester component which is poly-ε-caprolactone and/or poly[(ε-caprolactam)-co-(ε-caprolactone)] containing at least 10 % of crystalline phase and having the crystalline phase melting temperature lower than 65 °C, in the weight ratio (a):(b) in the range of 4:1 to 1:9. Additionally, method of preparation of such composition is described.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

Abrégé

Synthetic macromolecular conjugate for selective interaction with proteins has a synthetic copolymer, and at least one binding group and at least one further group selected from an affinity tag and an imaging probe, and at least one binding group and at least one further group being bound via covalent bond to the synthetic copolymer. The macromolecular conjugate is suitable in particular for identification, visualization, quantification or isolation of proteins and/or cells.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 33/531 - Production de matériaux de tests immunochimiques
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif
• C08F 8/30 - Introduction d'atomes d'azote ou de groupes contenant de l'azote
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées

Abrégé

The present invention relates to a method of preparation of a substrate surface containing carboxybetaine groups with bound bioactive substances, having resistance to undesirable deposition of biological media components on the substrate surface, comprising the steps of chemical activation of carboxybetaine groups on the surface of the substrate by converting the carboxybetaine carboxyl group into an active ester, covalent binding of a bioactive substance to some of the active esters, and reaction of the product from the previous step with an acid of general formula (I) NH2-(CH2-CH2-0)n-CH2-COOH, where n = 1 to 4, wherein the acid of general formula (I) reacts with those active esters, which have not undergone covalent bonding of the bioactive substance.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• C08F 122/22 - Esters contenant de l'azote

Abrégé

The present invention relates to a block copolymer for overcoming drug resistance of tumours to chemotherapy, comprising blocks A and B, connected to each other with a hydrolytically, reductively or enzymatically biodegradable linker, wherein the hydrophilic block A is formed by poly(N-(2-hydroxypropyl) methacrylamide), eventually containing comonomers enabling covalent binding of drugs, and the hydrophobic block B is formed by a polypropylene oxide. The invention relates also to a polymer conjugate containing the block copolymer and the low molecular weight drug, to a pharmaceutical composition containing them and to the use thereof in medicine.

Classes IPC  ?

• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 9/107 - Émulsions
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

The present invention relates to photoactivatable nanoparticles for photodynamic applications containing a photosensitizer, a (C8 to C22) fatty alcohol and a polymeric surfactant, preferably poly(ethylene oxide) monomethyl ether-block-poly(ε-caprolactone), whereas the size of the nanoparticle is in the range of from 1 to 1000 nm, and the core of the nanoparticle is solid at the temperature of 4 °C, and liquid at the temperature around 39 °C. The present invention further relates to a method of preparation of the photoactivatable nanoparticle, a pharmaceutical composition containing it, and use thereof.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/51 - Nanocapsules
• A61P 35/00 - Agents anticancéreux

Abrégé

Title of the invention: Method for preparation of polymeric materials The invention provides a method of preparation of a polymeric material, wherein at least one cyclic monomer is combined with hydrated layered double hydroxide of formula [M2+1-xM3+x(OH)2(Am-)x/m], wherein Am is an m-valent anion, M2+ is a divalent metal cation and M3+ is a trivalent metal cation, the value x is in the range of 0.20 < x < 0.33, whereas the hydrated layered double hydroxide is surface-modified by a ionic liquid containing a phosphonium cation in the amount of 0.1 to 9 wt. % relative to the weight of the hydrated layered double hydroxide, in weight ratio of the cyclic monomer to the surface-modified layered double hydroxide 100/1 to 10/1, and the resulting suspension is treated with electromagnetic irradiation with a frequency ranging from 915 to 2450 MHz at the temperature from 150 °C to 250 °C, preferably for 3 min to 120 min.

Classes IPC  ?

• C08K 9/04 - Ingrédients traités par des substances organiques
• C08G 59/22 - Composés diépoxydés
• C08G 63/78 - Procédés de préparation
• C08G 69/16 - Procédés de préparation

Abrégé

Polysaccharide based polymer and its use for the prevention and treatment of the Wilson's disease The present invention relates to polysaccharide based polymers modified by cross-linking and copper-binding groups, which are suitable as preparations for peroral administration for use in prevention and/or treatment of Wilson's disease.

Classes IPC  ?

• A61K 31/717 - Celluloses
• A61K 31/722 - ChitineChitosane
• A61K 31/738 - Polysaccharides réticulés

Abrégé

The present invention relates to the preparation and use of copolymers composed of N-(2- hydroxypropyl) methacrylamide (HPMAA) and carboxybetaine methacrylamide (CBMAA). The invention further describes polymer brushes having structure I S-R-polymer (I) wherein S is a substrate; R is a residue of a polymerization initiator or a RAFT agent bound to the substrate; and "polymer" is the copolymer of N-(2-hydroxypropyl) methacrylamide and carboxybetaine methacrylamide Furthermore, production of these polymer brushes, containing random or block copolymers grafted to or from a substrate is described. The copolymer brushes are suitable for protecting substrates from deposition and/or adhesion of biological substances, and/or against thrombus formation. The brushes functionalized by covalent attachment of bioactive substances to CBMAA monomer units are particularly suitable for specific interaction with target biological substances which is not affected by nonspecific deposition of non-target compounds.

Classes IPC  ?

• C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
• A61L 27/34 - Matériaux macromoléculaires
• A61L 31/10 - Matériaux macromoléculaires
• A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• C08F 220/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide

Abrégé

The present invention relates to the preparation and use of copolymers composed of N-(2- hydroxypropyl) methacrylamide (HPMAA) and carboxybetaine methacrylamide (CBMAA). The invention further describes polymer brushes having structure I S-R-polymer (I) wherein S is a substrate; R is a residue of a polymerization initiator or a RAFT agent bound to the substrate; and "polymer" is the copolymer of N-(2-hydroxypropyl) methacrylamide and carboxybetaine methacrylamide Furthermore, production of these polymer brushes, containing random or block copolymers grafted to or from a substrate is described. The copolymer brushes are suitable for protecting substrates from deposition and/or adhesion of biological substances, and/or against thrombus formation. The brushes functionalized by covalent attachment of bioactive substances to CBMAA monomer units are particularly suitable for specific interaction with target biological substances which is not affected by nonspecific deposition of non-target compounds.

Classes IPC  ?

• C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
• C08F 220/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide
• A61L 27/34 - Matériaux macromoléculaires
• A61L 31/10 - Matériaux macromoléculaires
• A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques

Abrégé

The present invention provides a composition for stabilization of polyethylene, consisting of a first component selected from the group comprising tocoferols, tocotrienols and 5 mixtures thereof, and of a second component which is a tetracycline antibiotic. Furthermore, the invention provides polyethylene comprising this mixture, preferably in an amount of at least 200 ppm, methods of production thereof, and implants for human or veterinary medicine comprising said stabilized polyethylene.

Classes IPC  ?

• A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• C08L 23/06 - Polyéthylène
• C08K 5/00 - Emploi d'ingrédients organiques

Abrégé

Macromolecular conjugates for isolation, immobilization and visualization of proteins The invention provides a synthetic macromolecular conjugate for selective interaction with proteins, comprising a synthetic copolymer, and at least one binding group and at least one further group selected from an affinity tag and an imaging probe, said at least one binding group and at least one further group being bound via covalent bond to said synthetic copolymer. The macromolecular conjugate is suitable in particular for identification, visualization, quantification or isolation of proteins and/ or cells. HPMA copolymer, i.e.poly(HPMA-co-Ma-ß-Ala-TT), a copolymer prepared by conventional solution radical polymerization or controlled radical copolymerization (e.g. RAFT copolymerization, reversible addition-fragmentation chain-transfer) of N-(2- hydroxypropyl) methacrylamide (HPMA) and 3-(3-methacrylamidopropanoyl) thiazolidine-2-thione (Ma-P-Ala-TT) can be preferably used as the basic copolymer.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Macromolecular conjugates for visualization and separation of proteins and cells The present invention descripbes macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells both in vitro and in vivo. HPMA copolymer, i.e.poly(HPMA-co-Ma-ß-Ala-TT), copolymer prepared by conventional solution radical polymerization or controlled radical copolymerization (e.g. RAFT copolymerization, reversible addition-fragmentation chain-transfer) of N-(2- hydroxypropyl)methacrylamide (HPMA) and 3-(3-methakrylamidopropanoyl)thiazolidine-2-thione (Ma-P-Ala-TT) can be preferably used as the basic copolymer.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• A61K 51/04 - Composés organiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/531 - Production de matériaux de tests immunochimiques
• C08F 20/28 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle ne contenant pas de cycles aromatiques dans la partie alcool
• C08F 20/34 - Esters contenant de l'azote
• C08F 20/54 - Amides

Abrégé

Macromolecular conjugates for isolation, immobilization and visualization of proteins The invention provides a synthetic macromolecular conjugate for selective interaction with proteins, comprising a synthetic copolymer, and at least one binding group and at least one further group selected from an affinity tag and an imaging probe, said at least one binding group and at least one further group being bound via covalent bond to said synthetic copolymer. The macromolecular conjugate is suitable in particular for identification, visualization, quantification or isolation of proteins and/ or cells. HPMA copolymer, i.e.poly(HPMA-co-Ma-β-Ala-TT), a copolymer prepared by conventional solution radical polymerization or controlled radical copolymerization (e.g. RAFT copolymerization, reversible addition-fragmentation chain-transfer) of N-(2- hydroxypropyl) methacrylamide (HPMA) and 3-(3-methacrylamidopropanoyl) thiazolidine-2-thione (Ma-P-Ala-TT) can be preferably used as the basic copolymer.

Classes IPC  ?

• G01N 33/531 - Production de matériaux de tests immunochimiques
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif
• C08F 20/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide

Abrégé

Macromolecular conjugates for visualization and separation of proteins and cells The present invention descripbes macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells both in vitro and in vivo. HPMA copolymer, i.e.poly(HPMA-co-Ma-β-Ala-TT), copolymer prepared by conventional solution radical polymerization or controlled radical copolymerization (e.g. RAFT copolymerization, reversible addition-fragmentation chain-transfer) of N-(2- hydroxypropyl)methacrylamide (HPMA) and 3-(3-methakrylamidopropanoyl)thiazolidine-2-thione (Ma-P-Ala-TT) can be preferably used as the basic copolymer.

Classes IPC  ?

• G01N 33/531 - Production de matériaux de tests immunochimiques
• A61K 49/00 - Préparations pour examen in vivo
• C08F 20/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif

Abrégé

The present invention relates to a preparation for oral use destined for prevention and treatment of inflammatory affections of gastrointestinal tract, said preparation containing a mucoadhesive, biocompatible hydrophilic polymer containing: - at least one type of structural units A selected from a group comprising units derived from acrylic and methacrylic acids and their salts, hydroxyalkyl acrylates and methacrylates, hydroxyalkyl acrylamides and methacrylamides, N,N-dialkylaminoalkyl acrylates and methacrylates, N,N-dialkylaminoalkyl acrylamides and methacrylamides, N- vinyl-2-pyrrolidone and mixtures thereof; - at least one type of structural units B selected from a group comprising units derived from hydroxy terminated (polyoxyethylene) acrylates and methacrylates, alkyloxy terminated (polyoxyethylene) acrylates and methacrylates, hydroxy terminated (polyoxyethylene) acrylamides and methacrylamides, alkyloxy terminated (polyoxyethylene) acrylamides and methacrylamides and mixtures thereof; and - at least one type of structural units C derived from sterically hindered amines.

Classes IPC  ?

• A61K 31/785 - Polymères contenant de l'azote
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/74 - Matières polymères synthétiques
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a preparation for oral use destined for prevention and treatment of inflammatory affections of gastrointestinal tract, said preparation containing a mucoadhesive, biocompatible hydrophilic polymer containing: - at least one type of structural units A selected from a group comprising units derived from acrylic and methacrylic acids and their salts, hydroxyalkyl acrylates and methacrylates, hydroxyalkyl acrylamides and methacrylamides, N,N-dialkylaminoalkyl acrylates and methacrylates, N,N-dialkylaminoalkyl acrylamides and methacrylamides, N- vinyl-2-pyrrolidone and mixtures thereof; - at least one type of structural units B selected from a group comprising units derived from hydroxy terminated (polyoxyethylene) acrylates and methacrylates, alkyloxy terminated (polyoxyethylene) acrylates and methacrylates, hydroxy terminated (polyoxyethylene) acrylamides and methacrylamides, alkyloxy terminated (polyoxyethylene) acrylamides and methacrylamides and mixtures thereof; and - at least one type of structural units C derived from sterically hindered amines.

Classes IPC  ?

• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/74 - Matières polymères synthétiques
• A61K 31/785 - Polymères contenant de l'azote
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to the method of preparation of a soluble block copolymer poly(styrene-block-C2-C4alkylene-stat-C2-C4alkylene-block-styrene) chloromethylated into a chloromethylation degree higher than 35 %. The principle of this method lies in a reaction of the starting block copolymer poly(styrene-block-C2-C4alkylene-stat-C2-C4alkylene-block-styrene) with dimethoxymethane, a chlorinating agent, and ZnCl2 catalyst, preferably at the temperature in the range of from 10 °C to 65 °C, with no direct use of chloroalkyl ethers and with no side cross-linking reaction. The invention further describes the use of this method for the preparation of homogeneous or microheterogeneous anion-exchange membranes, particularly by chloromethylated solution casting, its reaction with trialkylamine or trialkylphosphine, and their use for electrode impregnation in electrochemical devices, as catalyst carriers, for preparation of ion-exchange membranes and binders in electrochemical devices, ion-exchange applications and catalytic systems.

Classes IPC  ?

• B01J 47/12 - Procédés d'échange d'ions en généralAppareillage à cet effet caractérisés par l'emploi d'une substance échangeur d'ions sous forme de rubans, de filaments, de fibres ou de feuilles, p. ex. sous forme de membranes
• B01D 71/82 - Matériaux macromoléculaires non prévus spécifiquement dans un seul des groupes caractérisés par la présence de groupes déterminés, p. ex. introduits par un post-traitement chimique
• C08J 5/22 - Bandes, membranes ou diaphragmes
• C08F 8/24 - Haloalkylation

Abrégé

The invention relates to composite membranes for separation of gas mixtures consisting of compact or porous or asymmetric polymeric support and a thin separation layer of conjugated polymers such as polypyrrole or polyaniline and their derivatives. The separation layer of conjugated polymers is prepared by adsorption of monomers on a support and their subsequent in situ polymerization, when the molecules of support and conjugated polymers interpenetrate to form a transition layer. The thus prepared composite membranes are chemically and mechanically stable for a long time.

Classes IPC  ?

• B01D 69/12 - Membranes compositesMembranes ultraminces
• B01D 71/58 - Autres polymères contenant, dans la chaîne principale, uniquement de l'azote, avec ou sans oxygène ou carbone
• B01D 71/72 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, non prévus dans un seul des groupes

Abrégé

The present invention relates to water-soluble high-molecular-weight polymer drug carriers and their conjugates with drugs, derived from dendrimers of the amidoamine and 2,2-bis(hydroxymethyl)propanoic types, the amino and hydroxy end groups of which are attached to semitelechelic copolymers of N-(2 hydroxypropyl)methacrylamide (HPMA) through biodegradable spacers. The polymer carriers and conjugates enable targeted transport notably of anticancer drugs into solid tumors in which biodegradation, the associated controlled drug release and subsequent elimination of polymer carrier from the organism are provided. The polymer carrier conjugated with a cancerostatic for use in targeted therapy of human tumors.

Classes IPC  ?

• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• C08G 83/00 - Composés macromoléculaires non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a method of testing the local toxicity of a substance, characterized in that a cornea of an animal is exposed to the substance and the change in the corneal thickness is measured, and optionally also the change in the corneal light absorption or light transmission properties is measured. The change in the cornea thickness can be measured by a pachymeter, the change in the corneal absorption or transmission properties can be measured pectrophotometrically. The invention further relates to an insert to a cuvette for the spectrophotometric measurement. ˙

Classes IPC  ?

• G01N 21/03 - Détails de structure des cuvettes
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• A61F 9/01 - Traitement de la cornée
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 21/62 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente
• G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
• G01N 21/63 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité optiquement
• G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
• G02B 21/34 - Lames de microscope, p. ex. montage d'échantillons sur des lames de microscope

Abrégé

The invention relates to a biomaterial based on nanofibrillar layers, which consists of at least one nanofibrillar layer and living cells firmly connected with this nanofibrillar layer, wherein the nanofibrillar layer is formed by synthetic polymers or co-polymers of monomers selected from the group comprising methacrylic acid esters, methacrylic acid amides, poly urethanes, polyvinyl alcohols and polymers derived from lactic acid and its derivatives, and to a method of preparation thereof.

Classes IPC  ?

• A61L 27/38 - Cellules animales
• A61L 27/56 - Matériaux poreux ou cellulaires
• A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
• A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone

Abrégé

The invention relates to a method of cultivation of mesenchymal stem cells, wherein after aseptic separation of mononuclear cells from the marrow blood, said cells are seeded in low density into sterile plastic cultivation vessels and cultivated for approximately one to three weeks in CellGroTM Hematopoietic Stem Cell Medium, certified for the clinical use, with an addition of 10% human serum and supplements, wherein the supplements are added at least once in the course of the cultivation, without removal of hematopoietic cells and without medium exchange during the cultivation procedure, without any interference with the closed cultivation system, under the standard conditions for the cultivation of tissue cultures. For the cultivation of the mesenchymal stem cells in the closed cultivation system for the clinical use in the field of orthopaedic surgery, a simple bioreactor is proposed. The bioreactor consists of a cassette system containing cultivation vessels with filters for securing the sterile exchange of gas and with aseptic inlets for seeding and harvesting the cells and adding the supplements, and a carrier.

Classes IPC  ?

• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux